Journal
BIOTECHNOLOGY JOURNAL
Volume 10, Issue 10, Pages 1589-1599Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.201400757
Keywords
3D cell culture; Human pluripotent stem cells; Midi-scale bioreactor system; Stem cells
Funding
- German Federal State North Rhine Westphalia
- European Union [005-1007-0021]
- SCR&Tox consortium under the FP7-HEALTH-Alternative-Testing-Strategies of the European Union [266753]
- Hertie Foundation
Ask authors/readers for more resources
Reprogramming of patient cells to human induced pluripotent stem cells (hiPSC) has facilitated in vitro disease modeling studies aiming at deciphering the molecular and cellular mechanisms that contribute to disease pathogenesis and progression. To fully exploit the potential of hiPSC for biomedical applications, technologies that enable the standardized generation and expansion of hiPSC from large numbers of donors are required. Paralleled automated processes for the expansion of hiPSC could provide an opportunity to maximize the generation of hiPSC collections from patient cohorts while minimizing hands-on time and costs. In order to develop a simple method for the parallel expansion of human pluripotent stem cells (hPSC) we established a protocol for their cultivation as undifferentiated aggregates in a bench-top bioreactor system (BioLevitator). We show that long-term expansion (10 passages) of hPSCs either in mTeSR or E8 medium preserved a normal karyotype, three-germ-layer differentiation potential and high expression of pluripotency-associated markers. The system enables the expansion from low inoculation densities (0.3 x 10(5) cells/mL) and provides a simplified, cost-efficient and time-saving method for the provision of hiPSC at midi-scale. Implementation of this protocol in cell production schemes has the potential to advance cell manufacturing in many areas of hiPSC-based medical research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available